Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BEBT 209

Next Previous
Drug Profile

BEBT 209

Alternative Names: BEBT-209; KCBT-0191

Latest Information Update: 28 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Guangzhou BeBetter Medicine Technology
  • Developer BeBetter Med
  • Class Antineoplastics; Ketones; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HER2 negative breast cancer
  • Phase II/III Triple negative breast cancer
  • No development reported Breast cancer

Most Recent Events

  • 28 Aug 2026 No recent reports of development identified for phase-I development in HER2-negative-breast-cancer(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in China (PO, Capsule)
  • 04 Jun 2026 Phase-II/III clinical trials in Triple-negative-breast-cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in China (PO) (NCT07544056)
  • 29 May 2026 BeBetter Med completes a phase II trial in Triple-negative-breast-cancer (Late-stage disease, Recurrent, Metastatic disease, Combination therapy, Second-line therapy or greater) in China (PO) (NCT06685796)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top